Dr. Emmanuel Dulac Ph.D., Pharm.D. serves as Independent Director of the Company. Dr. Dulac has served as Chief Commercial Officer and Chief International Strategy at Alnylam Pharmaceuticals (Nasdaq: ALNY) since August 2016. Prior to Alnylam, Dr. Dulac was Senior Vice President, Global Head Rare Disease Business Unit, General Manager of United States Operations at Shire, plc (acquired by Takeda Pharmaceutical Company (NYSE:TAK)) from June 2014 to August 2016. Dr. Dulac held several leadership roles of increasing responsibility at Novartis (NYSE:NVS) from February 2006 to May 2014, including Vice President, Global Head Lung/Cystic Fibrosis. From August 2003 to February 2006, he served as Business Unit Lead for Cardiovascular Medicine at Abbott (NYSE:ABT). Dr. Dulac held several roles of increasing responsibility at Sanofi (Nasdaq:SNY) from October 1994 to August 2003, including Associate Director. Dr. Dulac earned a Doctorate in Pharmacology (PharmD, Ph.D.) from the University of Paris XI and IV and an M.B.A. from the ESSEC Business School in Paris.
Emmanuel Dulac is 51, he's been the Independent Director of Proteostasis Therapeutics Inc since 2019. There are 7 older and 2 younger executives at Proteostasis Therapeutics Inc. The oldest executive at Proteostasis Therapeutics Inc is Franklin Berger, 70, who is the Independent Chairman of the Board.
Emmanuel's mailing address filed with the SEC is C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON, MA, 02135.
Over the last 9 years, insiders at Proteostasis Therapeutics Inc have traded over $9,140,918 worth of Proteostasis Therapeutics Inc stock and bought 12,301,024 units worth $94,383,855 . The most active insiders traders include M James Barrett, Llc Fmr, and Bioventures Ltd Novartis Ag.... On average, Proteostasis Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $3,463,082. The most recent stock trade was executed by Enterprise Associates 12, L... on 26 November 2019, trading 1,283,919 units of PTI stock currently worth $3,222,637.
Proteostasis Therapeutics Inc executives and other stock owners filed with the SEC include: